Madhusmita Behera
Overview
Explore the profile of Madhusmita Behera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharma R, Sharma S, Shriwas P, Mehta L, Vu A, Mouw J, et al.
iScience
. 2024 Nov;
27(11):111133.
PMID: 39524367
Non-small cell lung cancer (NSCLC) collective invasion is supported by cooperativity of proliferative (follower) and invasive (leader) cells. H1299-isolated follower cells exhibit higher Yes-associated protein (YAP) expression, while leader cells...
2.
Sebastian N, Stokes W, Behera M, Jiang R, Gutman D, Huang Z, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39321212
Background: Preclinical data suggest antifungal azole derivatives have antitumor efficacy that may modulate response to immune checkpoint inhibitors (ICIs). We aimed to evaluate the association of azole drugs with overall...
3.
Behera M, Jiang R, Huang Z, Bunn B, Wynes M, Switchenko J, et al.
JTO Clin Res Rep
. 2024 Jun;
5(6):100592.
PMID: 38827378
Introduction: EGFR exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR tyrosine kinase inhibitor...
4.
Moghanaki D, Taylor J, Bryant A, Vitzthum L, Sebastian N, Gutman D, et al.
Clin Lung Cancer
. 2024 Mar;
25(3):225-232.
PMID: 38553325
Introduction: Lung cancer survival is improving in the United States. We investigated whether there was a similar trend within the Veterans Health Administration (VHA), the largest integrated healthcare system in...
5.
Lalonde C, Switchenko J, Behera M, Bilen M, Owonikoko T, Kaufman J, et al.
Oncologist
. 2023 Jul;
28(12):1055-1063.
PMID: 37418599
Racial and ethnic minority populations are consistently under-represented in oncology clinical trials despite comprising a disproportionate share of a cancer burden. Phase I oncology clinical trials pose a unique challenge...
6.
Khalil L, Huang Z, Zakka K, Jiang R, Penley M, Alese O, et al.
Pancreas
. 2023 Jun;
52(1):e75-e84.
PMID: 37378903
Objectives: Colloid carcinoma (CC) is a rare subtype of pancreatic carcinoma. The aims of the study are to characterize the clinicopathological features and to evaluate the overall survival (OS) of...
7.
Rollison D, M Levin G, Warner J, Pinder R, Havener L, Behera M, et al.
J Registry Manag
. 2023 Jun;
49(4):153-160.
PMID: 37260815
Cancer surveillance at the population level is a highly labor-intensive process, with certified tumor registrars (CTRs) manually reviewing medical charts of cancer patients and entering information into local databases that...
8.
Sebastian N, Stokes W, Behera M, Jiang R, Gutman D, Huang Z, et al.
Clin Lung Cancer
. 2023 Feb;
24(3):287-294.
PMID: 36804711
Background: Immune checkpoint inhibitors (ICI) are commonly used in the management of patients with advanced non-small cell lung cancer (NSCLC), but response is suboptimal. Preclinical data suggest ICI efficacy may...
9.
Seong C, Huang C, Boese A, Hou Y, Koo J, Mouw J, et al.
bioRxiv
. 2023 Feb;
PMID: 36747658
Oncogenic RAS mutations drive aggressive cancers that are difficult to treat in the clinic, and while direct inhibition of the most common KRAS variant in lung adenocarcinoma (G12C) is undergoing...
10.
Westergaard S, Rupji M, Franklin L, Behera M, Ramalingam S, Higgins K
Cancer Med
. 2022 Nov;
12(6):7339-7347.
PMID: 36444869
Introduction: Tobacco cessation is a critical but challenging intervention for cancer patients. Our National Cancer Institute-designated Comprehensive Cancer Center instituted a tobacco cessation program in 2019. This manuscript reports on...